WEBSITE GUIDE

USERGUIDE

Welcome to BioPharmCatalyst.

Our USERGUIDE provides an in-depth overview of tools for PREMIUM and NON-PREMIUM users. A summary of current tools available is noted below but we strongly recommend all users to read the USERGUIDE for a much more thorough overview.

BioPharmCatalyst is an online resource for stock market investors of biotech and pharmaceutical companies listed on U.S. markets (NASDAQ and NYSE). Approximately 550 companies are tracked. The primary function of BioPharmCatalyst is to track pipelines of drugs in clinical development. For a drug to receive marketing approval from the Food and Drug Administration (FDA), companies must conduct human clinical trials, generally in three phases (Phase 1-3) before submitting a regulatory filing, normally a New Drug Application, to the FDA for marketing approval. However, BioPharmCatalyst provides much more than just a database to track the development of drug pipelines. Throughout the USERGUIDE we will provide an overview as to which tools are available for both PREMIUM and NON-PREMIUM users and how to best use them.

-

KEY TOOLS – PREMIUM 14-DAY FREE TRIAL

1) FDA CALENDAR - lists upcoming catalysts from biotech and pharma companies listed on NASDAQ/NYSE stock exchanges. Approximately 1000 events are listed compared with the free version which displays the first 150 events in chronological order.

Personalized Calendar: Select which stocks to view by creating your own portfolio.

Select which columns to display. By default, the public version shows five columns (ticker, price, drug/indication, stage and catalyst). Premium users can add and choose from a list of around 20 columns.

Screener/filter: Display catalysts that satisfy specific criteria such as drug phase, market cap, indication, stock price, relative volume and short ratio.

2) COMPANY CASH DATABASE- displays a company's current cash position, cash burn, number of months of cash left, enterprise value.

3) PERSONALIZED PORTFOLIO

View the latest company press releases, articles and stock prices (20 min delay) from stocks in your portfolio, avoiding having to search through each of the respective company pages.

The Personalized Portfolio allows you to select a basket of companies to follow, rather than tracking all 550. Instructions on how to set up your Personalized Portfolio are available in the following video.

4) IPO CALENDAR – LOCK UP AND EXPIRY DATES

QUIET PERIOD for an IPO refers to a duration of time when analyst coverage must not be released to the public. Once this period EXPIRES, such information may be released by analysts or company management.

LOCK-UP PERIOD is a restriction placed on insiders from selling their shares post an IPO. A typical lock-up period lasts for 180 days, preventing insiders who bought or who were provided with shares during the IPO from flooding the market with many shares. Once the lock-up period expires, all such insiders are permitted to sell some or all their holdings.

5) BIOTECH EARNINGS CALENDAR

The BioPharmCatalyst Earnings Calendar displays expected earnings release dates for the current or upcoming earnings season. Estimated and Actual EPS (Earnings per share) data are also displayed.

Earnings releases for mid and large cap companies with established revenue streams from marketable drugs, should be considered as potential price moving catalysts. Much hype generated by companies, analysts and investors often surround the approval and launch of a drug. Earnings reports give an opportunity to garner whether or not such hype is warranted.

6) NOTIFICATIONS (desktop/email) - additions and date changes to the FDA Calendar and company-issued press releases.

-

FREE TOOLS AVAILABLE TO PREMIUM AND NON-PREMIUM MEMBERS

1) PDUFA CALENDAR

The PDUFA date refers to when the FDA is expected to deliver its decision to approve or reject a New Drug Application (NDA) or Biologics License Application (BLA). On the PDUFA date the FDA will either i) issue approval for marketing or ii) issue a Complete Response Letter (CRL) - i.e. rejection letter.

Generally, the company will release the outcome of the decision by the FDA on the actual PDUFA date. However, it is not uncommon for the press release to be issued the following day. If the PDUFA date lies on a weekend or public holiday, a press release is commonly issued prior to the date.

If a company is issued a PDUFA action date with PRIORITY REVIEW, the review period is shortened by four months. FDA approval decisions for such reviews are occasionally released several weeks in advance of the PDUFA date.

An Advisory Committee provides a forum to discuss issues regarding the drug. The expert panel will generally vote on efficacy and safety. The FDA, while not bound by the committee decision, tend to generally follow the advice of the committee when making its final approval decision. An Advisory Committee meeting is usually convened 2-4 months (approx.) prior to the PDUFA date.

2) HISTORICAL CATALYST DATABASE

The Historical Catalyst Database includes most key Phase 2 and 3 data releases, FDA approval and Complete Response Letters since 2015/16.

From 2009 through to 2015 most small/mid-cap FDA Approval and Complete Response Letters are also included.

3) IPO CALENDAR

The BioPharmCatalyst Biotech Stock IPO Calendar gives a brief rundown of upcoming Healthcare Initial Public Offerings (IPOs).

The Historical Biotech IPO Database tracks most Healthcare IPO listings over approximately the previous 24 months.

The database includes data such as the current return since the IPO. It is not uncommon to see IPOs gain well over 100% within just a couple years. Conversely, IPOs that have lost over half their value are just as common.

4) INDIVIDUAL COMPANY PAGES

Company specific information is available for over 550 biotech and pharma companies covered on BioPharmCatalyst (stock and chart data, drug pipelines and news headlines).

5) DAILY BIOTECH UPDATE

At the close of each after-hours session an update of the day’s price movers, major clinical readouts and regulatory news, are summarized together with pipeline updates provided by companies.

Readers can also access these updates by subscribing to our FREE NEWSLETTER, which is delivered daily at 8pm EST.

6) WEEKLY REVIEW AND WATCH LIST

The weekly review summarises key price movers over the week that was. A list of upcoming catalysts is also provided. The theme of the list changes from week to week, where key catalysts for the upcoming week, month or quarter might be highlighted.

This is also available by subscribing to our FREE NEWSLETTER, which is delivered weekly every Saturday morning.

7) BIOTECH STOCKS

Top 10 daily biotech stock GAINERS, LOSERS and UNUSUAL VOLUME are displayed.